Welcome to the investor section of Alligator Bioscience. We are a clinical-stage biotechnology company listed on Nasdaq Stockholm (ATORX), advancing tumor-directed immunotherapies with a focus on the CD40 pathway.
Our lead candidate, mitazalimab, is a Phase 3 ready asset in metastatic pancreatic cancer which is is complemented by a strong pipeline that offers additional immuno-oncology opportunities.
For further information, please contact Alligator at ir@alligatorbioscience.com.